Clinical trials
Respiratory Infection Virus clinical trials
Below are recruiting respiratory infection virus clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04484025Enrolling by invitationPhase 2
Study of an oral drug for hospitalized COVID-19 patients
This trial tests an oral drug called SPI-1005 for people hospitalized with moderate COVID-19. The drug may help reduce inflammation and protect the lungs, and the study will compare it to a placebo (a pill with no active medicine) to see if it helps people recover.
New Haven, ConnecticutAges 18 years+ - NCT05127980Recruiting
Study of immune antibodies after first-time EBV infection
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
BaselAges 18 years+ - NCT05336851Recruiting
Emergency breathing test study for sudden lung infections
This trial tests an emergency breathing-related approach for adults with a sudden, community-acquired respiratory infection. It may help doctors quickly sort out what’s going on and guide early care.
Hong KongAges 18–100 - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT04448145Recruiting
Study why COVID lasts after recovery
This study looks at what factors may make COVID-19 symptoms or infection effects last after someone has recovered. It also collects certain body samples to better understand why this persistence happens.
New York, New YorkAges 7 years+ - NCT07805590Recruiting
How respiratory viruses interact in hospitalized patients
This study looks at how different respiratory viruses interact in hospitalized patients during the winter seasons. It does not involve any new treatment or extra tests – it just reviews existing test results to learn more about these viruses.
Lyon, RhoneAges Any age - NCT07407569RecruitingPhase 2
HPV vaccine study for women with HPV16
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Antwerp, WilrijkAges 18–45 - NCT07852091RecruitingPhase 2
Combination therapy aiming for a functional cure for chronic hepatitis B
This study tests a new combination of medicines to help your immune system control the hepatitis B virus, with the goal of stopping the need for long-term treatment. It may be an option for people who have taken or are currently taking hepatitis B medications.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07845058RecruitingPhase 2
Combination therapy for a functional cure of chronic hepatitis B
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT06667063Recruiting
Immune response study for COVID-19 and flu
This study looks at how your immune system responds to COVID-19 or the flu. It may help researchers understand these infections better, whether you are currently sick or healthy.
Wuhan, HubeiAges 18 years+ - NCT07573943RecruitingPhase 4
ASC22 with Peg-IFN for chronic hepatitis B cure
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT06859333RecruitingPhase 1
Safety study of Ingavirin Forte in healthy volunteers
This trial tests how safe and tolerable different doses of Ingavirin Forte are in healthy people. It helps find the right dose for future studies.
MoscowAges 18–45 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05266222Recruiting
Collecting respiratory virus samples for a research library
This study collects samples from people who have or might have a cold/respiratory virus, then stores them for future research. It may help researchers better understand respiratory germs and develop better treatments.
Bethesda, MarylandAges 3 years+ - NCT03808922RecruitingPhase 3
DAS181 treatment for COVID-19 lung infection in immune-compromised adults
This Phase 3 trial tests DAS181 to treat lower lung (chest) viral infections in people with weakened immune systems, including a COVID-19 subgroup. It may help by targeting certain viruses in the lungs, but joining depends on your oxygen needs, recent diagnosis, and other safety factors.
Duarte, CaliforniaAges Any age - NCT06331364Recruiting
Treating lung infections with better antibiotic decisions in Sri Lanka
This study tests whether a new way of deciding when to use antibiotics helps patients with lower respiratory infections (like pneumonia or bronchitis) in Sri Lankan hospitals. If you were recently admitted with a new lung infection, you may be able to join.
BalapitiyaAges 14 years+ - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07645534RecruitingPhase 1
Testing a New Antiviral Medicine Formulation in Healthy Adults
This study compares two versions of an antiviral medicine called Ingavirin to see how your body processes them and whether they are safe. Researchers will give you the medicine on an empty stomach and after eating to understand how food affects how your body absorbs it.
Saint PetersburgAges 18–45 - NCT07149428Recruiting
Deep study of smell loss causes using brain scans
This study uses brain imaging and electrical recordings to understand the brain's role in smell loss from any cause—like COVID, sinus problems, or chemotherapy. You may be eligible if you have any degree of smell loss lasting under a year.
Bethesda, MarylandAges 18–99 - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT06873633RecruitingPhase 2
Testing remdesivir for RSV in hospitalized children under 2
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
BangkokAges birth–2 years - NCT06789159RecruitingPhase 1
VK-2019 for relapsed/refractory EBV-positive DLBCL
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Lexington, KentuckyAges 18 years+
Hear when a new Respiratory Infection Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory infection virus?
- Yes. Clin2 currently lists 78 recruiting respiratory infection virus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory infection virus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory infection virus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.